Kristina Nilsson Ekdahl

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12066374/publications.pdf

Version: 2024-02-01

49 papers 3,826 citations

30 h-index 206112 48 g-index

49 all docs

49 docs citations 49 times ranked 4186 citing authors

#	Article	IF	Citations
1	Complement and coagulation: strangers or partners in crime?. Trends in Immunology, 2007, 28, 184-192.	6.8	533
2	The role of complement in biomaterial-induced inflammation. Molecular Immunology, 2007, 44, 82-94.	2.2	384
3	Tissue Factor Produced by the Endocrine Cells of the Islets of Langerhans Is Associated With a Negative Outcome of Clinical Islet Transplantation. Diabetes, 2005, 54, 1755-1762.	0.6	294
4	Inhibition of Thrombin Abrogates the Instant Blood-Mediated Inflammatory Reaction Triggered by Isolated Human Islets: Possible Application of the Thrombin Inhibitor Melagatran in Clinical Islet Transplantation. Diabetes, 2002, 51, 1779-1784.	0.6	242
5	Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surface. Biomaterials, 2005, 26, 1477-1485.	11.4	171
6	Titanium Is a Highly Thrombogenic Biomaterial: Possible Implications for Osteogenesis. Thrombosis and Haemostasis, 1999, 82, 58-64.	3.4	165
7	C3 Adsorbed to a Polymer Surface Can Form an Initiating Alternative Pathway Convertase. Journal of Immunology, 2002, 168, 5786-5791.	0.8	135
8	Compstatin Inhibits Complement and Cellular Activation in Whole Blood in Two Models of Extracorporeal Circulation. Blood, 1998, 92, 1661-1667.	1.4	133
9	Dissecting the instant bloodâ€mediated inflammatory reaction in islet xenotransplantation. Xenotransplantation, 2008, 15, 225-234.	2.8	121
10	The tick-over theory revisited: Is C3 a contact-activated protein?. Immunobiology, 2012, 217, 1106-1110.	1.9	121
11	Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition?. Trends in Immunology, 2010, 31, 32-38.	6.8	119
12	A new in vitro model to study interaction between whole blood and biomaterials. Studies of platelet and coagulation activation and the effect of aspirin. Biomaterials, 1999, 20, 603-611.	11.4	118
13	Protection of Nonself Surfaces from Complement Attack by Factor H-Binding Peptides: Implications for Therapeutic Medicine. Journal of Immunology, 2011, 186, 4269-4277.	0.8	85
14	Optimal heparin surface concentration and antithrombin binding capacity as evaluated with human non-anticoagulated bloodin vitro. Journal of Biomedical Materials Research Part B, 2003, 67A, 458-466.	3.1	83
15	Dispersion of TiO2 nanoparticles improves burn wound healing and tissue regeneration through specific interaction with blood serum proteins. Scientific Reports, 2017, 7, 15448.	3.3	75
16	Material-specific thrombin generation following contact between metal surfaces and whole blood. Biomaterials, 2005, 26, 1397-1403.	11.4	69
17	Properdin binding to complement activating surfaces depends on initial C3b deposition. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E534-E539.	7.1	69
18	Tubing loops as a model for cardiopulmonary bypass circuits: Both the biomaterial and the blood-gas phase interfaces induce complement activation in anin vitro model. Journal of Clinical Immunology, 1996, 16, 222-229.	3.8	68

#	Article	IF	Citations
19	Mannose-Binding Lectin is Associated with Thrombosis and Coagulopathy in Critically Ill COVID-19 Patients. Thrombosis and Haemostasis, 2020, 120, 1720-1724.	3.4	63
20	Binding of a model regulator of complement activation (RCA) to a biomaterial surface: surface-bound factor H inhibits complement activation. Biomaterials, 2001, 22, 2435-2443.	11.4	57
21	Contact between a polymer and whole blood: Sequence of events leading to thrombin generation. Translational Research, 2001, 138, 139-145.	2.3	53
22	Hirudin versus heparin for use in whole blood <i>in vitro</i> biocompatibility models. Journal of Biomedical Materials Research - Part A, 2009, 89A, 951-959.	4.0	52
23	Complement Component C3 and Butyrylcholinesterase Activity Are Associated with Neurodegeneration and Clinical Disability in Multiple Sclerosis. PLoS ONE, 2015, 10, e0122048.	2.5	52
24	Activated human platelets induce factor XIIa-mediated contact activation. Biochemical and Biophysical Research Communications, 2010, 391, 11-17.	2.1	50
25	Complement C3b interactions studied with surface plasmon resonance technique. International Immunopharmacology, 2001, 1, 495-506.	3.8	49
26	Transfer of functional prostasomal CD59 of metastatic prostatic cancer cell origin protects cells against complement attack. Prostate, 2005, 62, 105-114.	2.3	45
27	Contribution of Chondroitin Sulfate A to the Binding of Complement Proteins to Activated Platelets. PLoS ONE, 2010, 5, e12889.	2.5	42
28	Complement Activation by CpG in a Human Whole Blood Loop System: Mechanisms and Immunomodulatory Effects. Journal of Immunology, 2009, 183, 6724-6732.	0.8	37
29	Distinctive regulation of contact activation by antithrombin and C1-inhibitor on activated platelets and material surfaces. Biomaterials, 2009, 30, 6573-6580.	11.4	35
30	Surface-attached PEO in the form of activated pluronic with immobilized factor H reduces both coagulation and complement activation in a whole-blood model. Journal of Biomedical Materials Research - Part A, 2006, 76A, 25-34.	4.0	33
31	Overexpression of ecto-protein kinases in prostasomes of metastatic cell origin. Prostate, 2006, 66, 675-686.	2.3	30
32	Phosphorylation of complement component C3 after synthesis in U937 cells by a putative protein kinase, casein kinase 2, which is regulated by CD11b: evidence that membrane-bound proteases preferentially cleave phosphorylated C3. Biochemical Journal, 1997, 328, 625-633.	3.7	28
33	Increased phosphate content in complement component C3, fibrinogen, vitronectin, and other plasma proteins in systemic lupus erythematosus. Covariation with platelet activation and possible association with thrombosis. Arthritis and Rheumatism, 1997, 40, 2178-2186.	6.7	28
34	Complement Activation on Radio Frequency Plasma Modified Polystyrene Surfaces. Journal of Colloid and Interface Science, 1993, 158, 121-128.	9.4	27
35	Complement activation in Lyme neuroborreliosis — Increased levels of C1q and C3a in cerebrospinal fluid indicate complement activation in the CNS. Journal of Neuroimmunology, 2007, 183, 200-207.	2.3	23
36	Contact activation products are new potential biomarkers to evaluate the risk of thrombotic events in systemic lupus erythematosus. Arthritis Research and Therapy, 2013, 15, R206.	3.5	19

#	Article	IF	CITATIONS
37	Absence of conformational change in complement factor 3 and factor XII adsorbed to acrylate polymers is related to a high degree of polymer backbone flexibility. Biointerphases, 2017, 12, 02D417.	1.6	14
38	Animal-Free Human Whole Blood Sepsis Model to Study Changes in Innate Immunity. Frontiers in Immunology, 2020, 11, 571992.	4.8	14
39	Potential of Cell Surface Engineering with Biocompatible Polymers for Biomedical Applications. Langmuir, 2020, 36, 12088-12106.	3.5	14
40	Prothrombotic effect of prostasomes of metastatic cell and seminal origin. Prostate, 2007, 67, 378-388.	2.3	13
41	Phosphorylation of Coagulation Factor XI by a Casein Kinase Released by Activated Human Platelets Increases Its Susceptibility to Activation by Factor XIIa and Thrombin. Thrombosis and Haemostasis, 1999, 82, 1283-1288.	3.4	13
42	Prothrombotic Effects of Prostasomes Isolated from Prostatic Cancer Cell Lines and Seminal Plasma. Seminars in Thrombosis and Hemostasis, 2007, 33, 080-086.	2.7	10
43	Development of an Immunoassay for the Detection of Minute Amounts of IgGâ€Coated Erythrocytes in Whole Blood and Its Application for the Assessment of Fcâ€Mediated Clearance of Antiâ€Dâ€Coated Erythrocytes in vivo. Vox Sanguinis, 1989, 57, 188-192.	1.5	9
44	Possible Immunoprotective and Angiogenesis-Promoting Roles for Malignant Cell-Derived Prostasomes: A New Paradigm for Prostatic Cancer?., 2006, 586, 107-119.		7
45	Genetic determinants of mannose-binding lectin activity predispose to thromboembolic complications in critical COVID-19. Nature Immunology, 2022, 23, 861-864.	14.5	7
46	Mapping pro―and antiangiogenic factors on the surface of prostasomes of normal and malignant cell origin. Prostate, 2010, 70, 834-847.	2.3	6
47	Compstatin Inhibits Complement and Cellular Activation in Whole Blood in Two Models of Extracorporeal Circulation. Blood, 1998, 92, 1661-1667.	1.4	6
48	Poly(2-aminoethyl methacrylate)-based polyampholyte brush surface with carboxylic groups to improve blood compatibility. Journal of Biomaterials Science, Polymer Edition, 2020, 31, 679-693.	3.5	4
49	Complement activation in individuals with previous subclinical Lyme borreliosis and patients with previous Lyme neuroborreliosis. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 855-862.	2.9	1